From Wound Care to Aesthetics: How Conexeu Plans to Capitalize on the Bio-Regeneration Market

Conexeu Sciences is pursuing a regenerative tissue platform designed to restore extracellular matrix (ECM) rather than simply replace lost volume, with initial development focused on wound care and longer-term potential in medical aesthetics and other fields. Miles Harrison, president and CEO, and Brian Pilcher, PhD, chief medical officer, met with Dermatology Times to discuss the company’s regulatory strategy and expanding applications for its investigational technology.

The company plans to pursue wound care as its initial regulatory indication through the US Food and Drug Administration’s 510(k) pathway for Class II medical devices. Harrison explained that the pathway allows a device to demonstrate substantial equivalence to a legally marketed predicate, potentially providing a more efficient route to commercialization. Conexeu aims to submit its 510(k) package by the end of 2026 or early 2027. If cleared, the indication would provide the company with manufacturing, regulatory, and commercial infrastructure that could support subsequent development programs.

The wound care application is particularly relevant to dermatology, including clinicians performing procedures that create tissue defects, such as Mohs surgery. The same ECM biology involved in wound repair is also disrupted through aging and substantial weight loss. Harrison and Pilcher see this overlap as an opportunity to develop the platform across seemingly distinct indications while maintaining a shared biological rationale.

The company estimates the US wound care market at approximately $2.6 billion and the aesthetics market at approximately $11 billion, with significant potential growth as use of GLP-1 medications continues to expand. As the executives noted, patients experiencing substantial weight loss may require more than traditional volume replacement because changes in adipose tissue can also affect tissue structure and quality. Conexeu’s long-term strategy includes exploring applications in aesthetics, breast reconstruction, dentistry, veterinary medicine, and other areas of tissue engineering. Harrison detailed a potential breast reconstruction application designed to support regeneration rather than relying exclusively on implants or tissue expanders.

Conexeu is continuing to evaluate the finding before publicly disclosing detailed results for an abstract readout. Harrison and Pilcher stressed that its technology remains investigational and is still undergoing preclinical development. The company’s stated long-term objective is to establish a regenerative tissue platform capable of supporting multiple clinical applications while developing a new category centered on “bio-regeneration.”

Missed part 1? Watch it here.